Non-Tech Stocks Rally as Biotech ETF Jumps 27% and J.B. Hunt Beats
Updated
Updated · CNBC · Jul 19
Non-Tech Stocks Rally as Biotech ETF Jumps 27% and J.B. Hunt Beats
1 articles · Updated · CNBC · Jul 19
Summary
J.B. Hunt and other non-tech names are outperforming despite a weak broader tape, suggesting the market is rewarding earnings and cyclical recovery outside technology.
27%-plus gains in the SPDR S&P Biotech ETF and J.B. Hunt’s upside earnings surprise point to active buying in biotech, transport, banks, retail, rails and airlines.
Wells Fargo is cited as another example: after analyst criticism, the stock recovered as investors focused on CEO Charlie Scharf’s push into higher-margin M&A and underwriting after cutting about 23% of staff.
That rotation is happening as tech remains under pressure from a leveraged unwind in memory and data-center trades, with names tied to hyperscalers and recent IPO enthusiasm still struggling.
The broader implication is a market imposing discipline on tech while capital shifts toward sectors with clearer valuations, consolidation potential and stronger near-term earnings momentum.